4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
4D Molecular Therapeutics (NASDAQ:FDMT) announced two upcoming presentations at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Long Beach, CA, from July 30 鈥� August 2, 2025.
The presentations will feature interim results from two clinical trials: the SPECTRA Phase 2a trial evaluating 4D-150 for Diabetic Macular Edema, including 52-week primary endpoint and 60-week analyses, and the PRISM Phase 2b trial evaluating 4D-150 for neovascular Age-related Macular Degeneration with 52-week results. Both presentations will be available on the company's website.
4D Molecular Therapeutics (NASDAQ:FDMT) ha annunciato due presentazioni in programma al 43掳 Meeting Scientifico Annuale della American Society of Retina Specialists (ASRS) che si terr脿 a Long Beach, CA, dal 30 luglio al 2 agosto 2025.
Le presentazioni mostreranno i risultati intermedi di due studi clinici: lo studio SPECTRA di Fase 2a che valuta 4D-150 per l鈥檈dema maculare diabetico, includendo l鈥檃nalisi del punto finale primario a 52 settimane e quella a 60 settimane, e lo studio PRISM di Fase 2b che valuta 4D-150 per la degenerazione maculare neovascolare legata all鈥檈t脿 con risultati a 52 settimane. Entrambe le presentazioni saranno disponibili sul sito web dell鈥檃zienda.
4D Molecular Therapeutics (NASDAQ:FDMT) anunci贸 dos presentaciones pr贸ximas en la 43陋 Reuni贸n Cient铆fica Anual de la American Society of Retina Specialists (ASRS) en Long Beach, CA, del 30 de julio al 2 de agosto de 2025.
Las presentaciones incluir谩n resultados interinos de dos ensayos cl铆nicos: el ensayo SPECTRA Fase 2a que eval煤a 4D-150 para edema macular diab茅tico, incluyendo el an谩lisis del punto final primario a las 52 semanas y a las 60 semanas, y el ensayo PRISM Fase 2b que eval煤a 4D-150 para la degeneraci贸n macular neovascular asociada a la edad con resultados a 52 semanas. Ambas presentaciones estar谩n disponibles en el sitio web de la compa帽铆a.
4D Molecular Therapeutics (NASDAQ:FDMT)電� 2025雲� 7鞗� 30鞚茧秬韯� 8鞗� 2鞚缄箤歆� 旌橂Μ韽媹鞎� 搿彪箘旃橃棎靹� 臧滌禍霅橂姅 鞝�43須� 氙戈淡 毵濍 鞝勲鞚� 頃欗殞(ASRS) 鞐半 瓿柬暀 須岇潣鞐愳劀 霊� 瓯挫潣 氚滍憸毳� 鞓堨爼頃橁碃 鞛堧嫟瓿� 氚滍憸頄堨姷雼堧嫟.
鞚措矆 氚滍憸鞐愳劀電� 霊� 瓯挫潣 鞛勳儊鞁滍棙 欷戧皠 瓴瓣臣毳� 瓿店皽頃╇媹雼�: 雼闺嚚氤戩劚 頇╇皹攵�膦� 旃橂鞝� 4D-150鞚� 韽夑皜頃橂姅 SPECTRA 2a靸� 鞁滍棙鞙茧, 52欤� 欤检殧 韽夑皜 鞁滌爯瓿� 60欤� 攵勳劃 瓴瓣臣毳� 韽暔頃橂┌, 雮橃澊 甏�霠� 鞁犾儩順堦磤靹� 頇╇皹氤�靹� 旃橂鞝� 4D-150鞚� 韽夑皜頃橂姅 PRISM 2b靸� 鞁滍棙鞚� 52欤� 瓴瓣臣霃� 氚滍憸霅╇媹雼�. 霊� 氚滍憸 氇憪 須岇偓 鞗轨偓鞚错姼鞐愳劀 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
4D Molecular Therapeutics (NASDAQ:FDMT) a annonc茅 deux pr茅sentations 脿 venir lors de la 43e r茅union scientifique annuelle de l'American Society of Retina Specialists (ASRS) qui se tiendra 脿 Long Beach, Californie, du 30 juillet au 2 ao没t 2025.
Les pr茅sentations porteront sur les r茅sultats interm茅diaires de deux essais cliniques : l'essai SPECTRA de phase 2a 茅valuant le 4D-150 pour l'艙d猫me maculaire diab茅tique, incluant les analyses du crit猫re principal 脿 52 semaines et 脿 60 semaines, ainsi que l'essai PRISM de phase 2b 茅valuant le 4D-150 pour la d茅g茅n茅rescence maculaire n茅ovasculaire li茅e 脿 l'芒ge avec des r茅sultats 脿 52 semaines. Les deux pr茅sentations seront disponibles sur le site internet de la soci茅t茅.
4D Molecular Therapeutics (NASDAQ:FDMT) gab zwei bevorstehende Pr盲sentationen auf dem 43. Jahrestreffen der American Society of Retina Specialists (ASRS) in Long Beach, Kalifornien, vom 30. Juli bis 2. August 2025 bekannt.
Die Pr盲sentationen zeigen Zwischenresultate aus zwei klinischen Studien: der SPECTRA Phase-2a-Studie, die 4D-150 bei diabetischem Makula枚dem untersucht, einschlie脽lich der 52-Wochen-Hauptendpunkt- und 60-Wochen-Analysen, sowie der PRISM Phase-2b-Studie, die 4D-150 bei neovaskul盲rer altersbedingter Makuladegeneration mit 52-Wochen-Ergebnissen bewertet. Beide Pr盲sentationen werden auf der Website des Unternehmens verf眉gbar sein.
- None.
- None.
EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics聽(Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced podium presentations at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Long Beach, CA, from July 30 鈥� August 2, 2025.
ASRS 2025 Presentation Details:
| Title: | Interim Results from the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Diabetic Macular Edema* |
| Date/Time: | Thursday, July 31, 2025 (11:35 鈥� 11:38 a.m. PT) |
| Presenter: | David Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS, Erie Retina Research, PA |
*Includes 52-week primary endpoint analysis and 60-week analysis (all patients have reached 60 weeks as of the data cutoff date of May 2, 2025)
| Title: | PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Neovascular Age-related Macular Degeneration: 52-week Results |
| Date/Time: | Friday, August 1, 2025 (11:24 鈥� 11:27 a.m. PT) |
| Presenter: | John A. Wells, MD, FACS, Palmetto Retina Center, SC |
The presentations will also be available on the 4DMT website:
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company鈥檚 lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company鈥檚 lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company鈥檚 second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics鈩�, 4DMT鈩�, Therapeutic Vector Evolution鈩�, and the 4DMT logo are trademarks of 4DMT.
All of the Company鈥檚 product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company鈥檚 product candidates for the therapeutic uses for which they are being studied.
Learn more at and follow us on .
Contacts:
Media:
Jenn Gordon
dna Communications
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
FAQ
When will 4D Molecular Therapeutics (FDMT) present at ASRS 2025?
What clinical trials will FDMT present at ASRS 2025?
Where can investors access FDMT's ASRS 2025 presentations?
What data will be presented in FDMT's SPECTRA trial presentation?
